Current oncology最新文献

{"title":"Targeted Hotspot Mutation Analysis of KRAS, TP53, and PTEN in Endometrial Cancer Revealed by Next-Generation Sequencing.","authors":"Salar Saadi Hussain, Zahra Abdulqader Amin","doi":"10.3390/curroncol33100601","DOIUrl":"https://doi.org/10.3390/curroncol33100601","url":null,"abstract":"<p><p>Endometrial cancer (EC) is a heterogeneous malignancy characterized by diverse molecular and clinicopathological features. This study investigated somatic mutations in three hotspot-region genes commonly implicated in EC pathogenesis (KRAS, TP53, PTEN) and their associations with clinical characteristics and biomarkers, rather than comprehensive genomic profiling. Targeted next-generation sequencing (NGS) was used to analyze hotspot regions of KRAS (exons 2 and 4), TP53 (exons 4 and 7), and PTEN (exon 2), while mutation parameters, including mutant allele frequency (MAF), allelic depth, and variant frequency, were assessed alongside clinicopathological data. Pathogenic KRAS missense mutations (p.G12D and p.A146V), TP53 missense (p.G245C) and stop-gain (p.W91*) variants, and a pathogenic PTEN mutation (p.D52Y) were identified, with MAF values ranging from 36.2% to 77.1%. One patient also exhibited microsatellite instability-high (MSI-H) status. Serum CA125 concentrations were significantly higher in serous carcinoma than in endometrioid carcinoma and non-malignant cases, suggesting potential prognostic rather than diagnostic value. This suggests an association between CA125 levels and histological subtype rather than diagnostic or prognostic value, as this study did not evaluate survival, recurrence, or longitudinal outcomes. The detected mutations highlight disruptions in estrogen signaling, DNA damage response, and PI3K/AKT pathway regulation, illustrating the diversity of alterations detectable within these three hotspot regions in EC. These findings provide insight into the mutational status of KRAS, TP53, and PTEN hotspot regions in endometrial cancer and support the potential use of identified genetic alterations as biomarkers for precision medicine and targeted therapeutic strategies, while indicating that CA125's clinical utility in EC, whether diagnostic or prognostic, remains to be established through outcome-based studies. This also reinforces CA125's limited diagnostic but possible prognostic role in EC management.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Utility of Drug-Eluting Beads Bronchial Arterial Chemoembolization in Advanced Refractory Non-Small Cell Lung Cancer.","authors":"Yawei Li, Junqing Xi, Yuxi Liu, Xiao Li, Xiaowu Zhang","doi":"10.3390/curroncol33100600","DOIUrl":"https://doi.org/10.3390/curroncol33100600","url":null,"abstract":"<p><p><b>Objective:</b> This study mainly focused on evaluating the efficacy and safety of drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) in treating advanced refractory non-small cell lung cancer (NSCLC) patients, with an exploratory investigation of whether combining DEB-BACE with anlotinib could bring additional benefits and identification of key prognostic factors. <b>Methods:</b> A retrospective analysis was conducted on 104 eligible patients, including 64 who received DEB-BACE monotherapy and 40 who received DEB-BACE combined with anlotinib. Kaplan-Meier method, log-rank test, and Cox proportional hazard model were used for survival and prognostic analyses. Primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). <b>Results:</b> The entire cohort had a median PFS of 13.9 months and median OS of 17.0 months, suggesting a potential survival benefit of DEB-BACE in advanced NSCLC. As an exploratory analysis, the combination group showed numerical advantages in PFS (13.9 vs. 10.6 months), OS (20.3 vs. 14.0 months), and ORR, without significant differences (all <i>p</i> > 0.05). ECOG 2 was an independent poor prognostic factor for PFS (<i>HR</i> = 2.602, <i>p</i> = 0.020) and tended to affect OS (<i>HR</i> = 2.259, <i>p</i> = 0.050). No grade 4 AEs or treatment-related deaths occurred; the 5.8% grade 3 AEs were all manageable. <b>Conclusions:</b> DEB-BACE may be effective and safe as a treatment option for advanced NSCLC patients, although prospective controlled studies are needed to confirm these findings. The combination of DEB-BACE with anlotinib, as an exploratory strategy, shows numerical benefits but no significant superiority.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise During Active Surveillance for Localized Low-Risk Prostate Cancer: Current Evidence and a Survivorship Framework.","authors":"Joseph A Miller","doi":"10.3390/curroncol33100599","DOIUrl":"https://doi.org/10.3390/curroncol33100599","url":null,"abstract":"<p><strong>Background: </strong>Active Surveillance (AS) is an established management strategy for appropriately selected men with localized low-risk prostate cancer, allowing many to defer or avoid definitive treatment while remaining under structured oncologic monitoring. Because surveillance may continue for years, survivorship needs during this period warrant greater attention.</p><p><strong>Objective: </strong>This narrative and conceptual review summarizes current evidence regarding structured exercise during AS and proposes a survivorship framework for individualized exercise prescription, including readiness monitoring as an emerging concept.</p><p><strong>Evidence synthesis: </strong>Exercise-oncology evidence and AS-specific trials support benefits in cardiorespiratory fitness and selected psychosocial outcomes. A 2024 systematic review and meta-analysis of six randomized trials (332 participants) found improved VO2peak, while effects on quality of life and PSA were less certain. Recent reviews likewise conclude that exercise and other lifestyle interventions are feasible and may provide supportive benefits, but evidence remains insufficient to demonstrate consistent effects on biopsy upgrading, MRI progression, durable deferral of treatment, or long-term prostate cancer outcomes. Readiness monitoring, including potential use of the Hooper Wellness Index, has not been validated in this population and is therefore hypothesis-generating rather than established clinical practice.</p><p><strong>Conclusions: </strong>Exercise appears well positioned as one component of a broader survivorship strategy during AS. Its current value is best supported for health, fitness, function, and well-being rather than as an anticancer treatment, and it should complement rather than replace evidence-based oncologic surveillance.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Journey and Treatment Patterns of Non-Muscle-Invasive Bladder Cancer in Mexico.","authors":"Anna Scavuzzo, Ricardo Alonso Castillejos-Molina, Iván Bravo-Castro, Miguel A Jiménez-Ríos, José G Campos-Salcedo, Miguel A Jiménez-Dávila, Brenda Suaste-Carmona, Lucía E Flores-García, Dominihemberg Ferreira, Victoria Castillo, Gabriela Lugo-Martínez, Francisco T Rodríguez Covarrubias","doi":"10.3390/curroncol33100597","DOIUrl":"https://doi.org/10.3390/curroncol33100597","url":null,"abstract":"<p><p>Non-muscle-invasive bladder cancer (NMIBC) accounts for most newly diagnosed bladder tumors, yet little is known about how it is managed in Mexico, particularly during prolonged Bacillus Calmette-Guérin (BCG) shortages. This retrospective, multicenter observational study characterized the clinical and histopathological profile, the diagnostic and treatment timelines, and the adherence to guideline-recommended care of patients with NMIBC treated at three tertiary referral hospitals in Mexico City. The records of 221 adults diagnosed between January 2010 and December 2020 were reviewed, and the risk of recurrence or progression was classified according to the European Association of Urology 2019 classification. The median age was 68 years (interquartile range [IQR] 59-75) and the male-to-female ratio was 3:1. Hematuria was the most frequent presenting symptom (83.3%). Three-quarters of patients had T1 tumors, 6.3% had concomitant carcinoma in situ, 84.6% had high-grade tumors, and 92.8% were at high risk of recurrence or progression. The median interval from symptom onset to histopathologic diagnosis was 167 days (IQR 81-329) and varied between centers. After diagnosis, the median time to second-look resection was 67 days (IQR 33.5-112) and to the first BCG instillation 92.5 days (IQR 41.8-165.5). Adjuvant intravesical therapy was administered to 66% of patients, most often BCG, although fewer than half of the BCG-treated patients (45%) completed induction, and 40% of the patients eligible for a second-look transurethral resection did not undergo it. Thirty percent of patients had no documented post-treatment surveillance. These real-world data provide a baseline description of NMIBC care in Mexican tertiary centers and identify specific, measurable gaps that may inform standardization and quality-improvement efforts in resource-constrained settings.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Association of the Two-Cycle On-Treatment CRAFITY Score in Advanced HCC: A Single-Center Retrospective Cohort Study.","authors":"Xiaochun Chen, Xinkun Guo, Guobin Chen, Susu Zheng, Yanfang Wu, Jingfang Wu, Hong Chen, Zhenzhen Zhang, Boheng Zhang","doi":"10.3390/curroncol33100598","DOIUrl":"https://doi.org/10.3390/curroncol33100598","url":null,"abstract":"<p><p>The baseline CRAFITY score, derived from AFP and C-reactive protein, is a validated prognostic biomarker for hepatocellular carcinoma (HCC) patients receiving immunotherapy. However, whether its prognostic value can be improved by on-treatment reassessment remains unclear. We evaluated the two-cycle on-treatment CRAFITY score in 108 advanced-HCC patients who received immune-based combination therapy as first- or second-line treatment. The score was calculated at baseline and after two cycles. Kaplan-Meier, Cox regression, time-dependent ROC, landmark, and sensitivity analyses were performed. The two-cycle score significantly stratified overall survival (median OS from landmark: 34.6, 12.9, and 6.7 months for scores 0, 1, and 2; <i>p</i> < 0.0001) and remained independently associated with OS after adjustment for vascular invasion, treatment line, and concomitant transarterial chemoembolization (TACE) (HR 2.36, 95% CI 1.70-3.29, <i>p</i> < 0.001). The baseline score showed only borderline associations (OS <i>p</i> = 0.07; PFS <i>p</i> = 0.09). The two-cycle score had an apparent AUC of 0.709 (95% CI 0.586-0.832) at 6 months and 0.745 (95% CI 0.658-0.832) at 12 months. The corresponding values for the baseline score were 0.645 and 0.638. Adding the two-cycle score to a clinical reference model increased the 12-month AUC from 0.699 to 0.811 (ΔAUC = 0.112). Bootstrap internal validation yielded an optimism-corrected C-index of 0.698 (95% CI 0.650-0.776). In conclusion, the two-cycle CRAFITY score provides complementary posttreatment prognostic information for early risk stratification, but prospective external validation is required before clinical application.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Up-Front Immune Checkpoint Inhibitors in Patients with Multiple Synchronous Primary Tumors, Including dMMR/MSI-H Gastrointestinal Malignancies: A Case Series and Review of the Literature.","authors":"Angela Damato, Martina Rotolo, Nicoletta Sparacino, Eleonora Borghi, Giacomo Santandrea, Angelina Filice, Mario Larocca, Carmine Pinto","doi":"10.3390/curroncol33100594","DOIUrl":"https://doi.org/10.3390/curroncol33100594","url":null,"abstract":"<p><p>The management of patients with multiple synchronous primary tumors remains challenging, particularly in individuals who are not candidates for surgery. While immune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy in deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) tumors, evidence supporting their use as a non-operative strategy in patients with multiple malignancies is limited, as this population is excluded from clinical trials. We report three cases of patients with synchronous primary tumors, including gastrointestinal malignancies with dMMR status, treated with up-front ICIs. Treatment strategies were individualized based on the patient's clinical condition, tumor burden, and molecular profile. All patients achieved meaningful and durable responses with long-term survival exceeding two to four years, supporting the feasibility of a non-operative strategy and organ preservation in carefully selected patients, including the frail subgroup population. Immunotherapy-based approaches were well tolerated, with a manageable safety profile. Notably, none of our patients underwent surgical resection. However, these observations are hypothesis-generating and cannot establish the efficacy or equivalence of immunotherapy to standard surgical management. Our findings extend current evidence to a largely underrepresented population and support a personalized, multidisciplinary, response-adapted approach. Prospective studies are warranted to better define patient selection, optimal treatment duration, and long-term outcomes of non-operative strategies in this setting.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Societal and Healthcare Costs of Post-IDFS Events Following Adjuvant Ribociclib Plus an Aromatase Inhibitor (AI) Versus AI Alone in Pre- and Postmenopausal Women with Early HR+/HER2- Breast Cancer in Canada.","authors":"Dina Soliman, Christine Brezden-Masley, Sandeep Sehdev, Natalia Sabater Anaya, Sophie Boukouvalas, Talitha Vincken","doi":"10.3390/curroncol33100595","DOIUrl":"https://doi.org/10.3390/curroncol33100595","url":null,"abstract":"<p><strong>Background: </strong>Recent advancements in early breast cancer (EBC) for high-risk populations have significantly improved invasive disease-free survival (IDFS). While cost-effectiveness has been assessed, the broader societal impact of improved IDFS remains unstudied. A non-homogeneous semi-Markov model was developed to estimate total healthcare and societal costs after first-line treatment with ribociclib plus an aromatase inhibitor (AI) or, alternatively, AI alone in patients with hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) EBC.</p><p><strong>Methods: </strong>Using an incidence-based approach, the model calculated total expected annual societal costs of disease-related events after cessation of adjuvant treatment with ribociclib plus AI or AI alone for HR+/HER2- EBC. The model includes five states: IDFS, non-metastatic recurrence (NMR), distant recurrence (DR), secondary primary malignancy (SPM) and death, with a one-year cycle length, and a new cohort entering each year. Health state transition probabilities are based on a previously published cost-effectiveness model (CEM). Costs are tallied only after IDFS (after cessation of adjuvant treatment) and include direct costs of medical care as well as indirect costs related to employment, productivity, and wage loss.</p><p><strong>Results: </strong>At the 4-year NATALEE data cut-off (April 2024), ribociclib plus AI reduced the risk of an IDFS event by 28.5% versus AI alone (HR 0.715), corresponding in the model to 23% fewer non-fatal events (NMR, DR, and SPM), 18% lower mortality, 23% lower total direct costs (-$957,471,465), and 24% lower indirect costs (-$448,542,692) from the period of cessation of adjuvant therapy until death. Healthcare savings were driven primarily by fewer distant recurrences and deaths, while societal savings were largely due to reduced caregiver costs.</p><p><strong>Conclusions: </strong>Treatments that reduce disease recurrence and mortality can significantly lower societal costs and alleviate burden on the healthcare system.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Antinuclear Antibody in Predicting the Efficacy and Immune-Related Adverse Events of Immunochemotherapy in Esophageal Squamous Cell Carcinoma: A Real-World Analysis.","authors":"Ansu Li, Yue Tao, Kongcheng Wang, Haifei Yang, Jiayao Yan, Wu Sun, Wei Ren","doi":"10.3390/curroncol33100596","DOIUrl":"https://doi.org/10.3390/curroncol33100596","url":null,"abstract":"<p><p><b>Background:</b> Programmed cell death protein 1 (PD-1) inhibitor-based immunochemotherapy is a standard treatment for advanced esophageal squamous cell carcinoma (ESCC), but accessible blood-based biomarkers associated with both treatment efficacy and the risk of immune-related adverse events (irAEs) remain limited. The presence of antinuclear antibody (ANA) in the pretreatment period may reflect host immune status; however, its clinical relevance in ESCC and its relationship with programmed death-ligand 1 (PD-L1) expression have not been fully characterized. <b>Methods:</b> We retrospectively enrolled 180 patients with ESCC who received PD-1 inhibitor-based immunochemotherapy. Baseline characteristics, tumor responses, survival outcomes, and irAEs were evaluated according to pretreatment ANA status. An additional sensitivity analysis was conducted among 103 patients with available PD-L1 results. Cox regression models with time-varying coefficients were applied when the proportional hazards assumption was not satisfied. <b>Results:</b> The ANA-positive rate was 36.67% (66/180). Compared to patients who were ANA-negative, those who were ANA-positive demonstrated superior objective response rates (71.21% vs. 46.49%, <i>p</i> = 0.002), longer median progression-free survival (PFS; 11.93 vs. 5.93 months) and longer median overall survival (OS; 25.20 vs. 14.77 months, both <i>p</i> < 0.01). In addition, they had a higher rate of all-grade irAEs (60.61% vs. 35.96%, <i>p</i> = 0.001), especially thyroid dysfunction (28.79% vs. 8.77%, <i>p</i> < 0.001). Multivariable time-varying Cox models linked ANA positivity to favorable PFS (hazard ratio [HR] = 0.14, 95% confidence interval [CI]: 0.04-0.46, <i>p</i> = 0.001) and OS (HR = 0.06, 95% CI: 0.01-0.52, <i>p</i> = 0.011). In the sensitivity cohort, ANA remained predictive for both survival endpoints, while PD-L1 did not. <b>Conclusions:</b> Pretreatment ANA positivity was associated with higher response rates, longer survival, and a higher incidence of irAEs in patients with ESCC receiving PD-1 inhibitor-based immunochemotherapy. These exploratory findings require prospective validation before ANA can be used to guide treatment decisions or assess individual irAE risk.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Treatment Utilization and Patterns of Adjuvant Olaparib for Early-Stage Breast Cancer: Insights from the Komodo Research Database.","authors":"Felipe Batalini, Qixin Li, Jennifer F Hayes, Kathryn Mishkin, Neel Vaidya, Dana Stafkey, Eileen Farrelly, Xiaoqing Xu","doi":"10.3390/curroncol33100589","DOIUrl":"https://doi.org/10.3390/curroncol33100589","url":null,"abstract":"<p><p><b>Background and Objectives:</b> As adjuvant treatment for human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer (eBC) evolves, real-world data should inform olaparib utilization, sequencing, and combination patterns in clinical practice. <b>Methods:</b> Using Komodo US claims data (1 January 2019-31 December 2023), we retrospectively analyzed HER2-negative eBC patients on adjuvant olaparib. Continuous insurance for 12 months pre- and ≥30 days post-index date (first olaparib prescription), with follow-up through disenrollment or study end, was required. Outcomes, including time on therapy (Kaplan-Meier median persistence), adherence (proportion of days covered), dose reduction, and combination patterns, were stratified by claims-derived hormone-receptor-positive (HR+) and triple-negative BC (TNBC) status. <b>Results:</b> Among 176 olaparib-treated patients (median age, 44 years), the median (95% CI) time on therapy was 11.0 (9.2, 12.2) months; 27.3% (n = 48) discontinued before 12 months without re-initiating, 19.9% experienced a dose reduction, and median adherence was 90%. Olaparib was combined with other therapies in 48.3% (n = 85) (29.6% [32/108] of TNBC and 77.9% [53/68] of HR+ patients), most often with immunotherapy in TNBC (81.3%, n = 26) and endocrine therapy in HR+ (88.7%, n = 47). <b>Conclusions:</b> Real-world data suggest favorable persistence and dosing patterns with adjuvant olaparib. Future research should prioritize olaparib combination regimen safety and effectiveness.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors.","authors":"Hilal Karakaş, Safa Can Efil, Burak Bilgin, Mehmet Ali Nahit Şendur, Murat Bardakçı, Perihan Perkin, Yakup Ergun","doi":"10.3390/curroncol33100590","DOIUrl":"https://doi.org/10.3390/curroncol33100590","url":null,"abstract":"<p><strong>Background: </strong>Reliable biomarkers that predict outcomes with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) remain limited. ABO blood group antigens may influence tumor immunity and response to immunotherapy.</p><p><strong>Methods: </strong>We retrospectively analyzed 239 patients with advanced NSCLC treated with ICI-based therapy between 2019 and 2024. Patients were classified according to ABO blood group, and overall survival (OS), progression-free survival (PFS), and treatment response were evaluated.</p><p><strong>Results: </strong>Patients with blood group O had significantly longer OS (18.6 vs. 11.0 months; <i>p</i> < 0.001) and PFS (9.4 vs. 4.2 months; <i>p</i> = 0.001) than patients with non-O blood groups. In multivariable analyses, blood group O remained independently associated with improved OS and PFS.</p><p><strong>Conclusions: </strong>Blood group O may represent a simple and readily available host-related prognostic marker in patients with advanced NSCLC receiving ICI-based therapy. Prospective multicenter studies are required to validate these findings.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}